Monogram Health closes $375 million of new funding for kidney, polychronic care model
Click Here to Manage Email Alerts
Monogram Health announced it received $375 million to continue deploying its in-home kidney and polychronic care delivery model in addition to its clinical services, according to a press release.
Services offered include complex case and disease management, utilization management and medication therapy management. The in-home and polychronic model is designed to improve patient outcomes and quality of life for patients with kidney disease and comorbid metabolic disorders while also reducing medical costs.
The $375 million in funding was invested by CVS Health, Cigna Ventures, Humana, Memorial Hermann Health System, and SCAN, as well as from both new and existing financial investors including TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments, Norwest Venture Partners and others.
“Kidney disease impacts a disproportionate share of disadvantaged communities and communities of color. Monogram has made bold strides in offering patients and families enhanced access to much needed health services, while substantially improving the overall affordability of their care,” Sen. Bill Frist, MD, board chair at Monogram and partner with Frist Cressey Ventures, said in the release. “This latest milestone growth funding round with substantive new and existing partners is driven by our disciplined commitment to, and demonstration of, outstanding clinical results. These better-quality outcomes for patients are made possible by our transformative approach to offering in-home, evidence-based nephrology and polychronic care.”
Read more about
Click Here to Manage Email Alerts